GENOR BIOPHARMA DL-00002 (67N0) — Financial Flexibility Index
GENOR BIOPHARMA DL-00002 (67N0) has a Financial Flexibility Index of -0.87x as of December 2024. Free cash flow of €-120.41 Million (operating CF €-121.98 Million minus capex €1.57 Million) represents -1% of total liabilities (€138.05 Million). Also explore how fast is GENOR BIOPHARMA DL-00002 growing its equity to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
GENOR BIOPHARMA DL-00002 Financial Flexibility Index (2021–2024)
Historical Financial Flexibility Index trend for GENOR BIOPHARMA DL-00002 across 4 annual periods. See GENOR BIOPHARMA DL-00002 balance sheet quality to measure how much of total assets are equity-financed.
Annual Financial Flexibility Index for GENOR BIOPHARMA DL-00002 (2021–2024)
Year-by-year free cash flow to debt coverage for GENOR BIOPHARMA DL-00002. For the full company profile including market capitalisation, see GENOR BIOPHARMA DL-00002 market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.87x | €-120.41 Million | €-121.98 Million | €138.05 Million | ▲ +47.3% |
| 2023 | -1.66x | €-424.09 Million | €-425.12 Million | €256.18 Million | ▲ +9.2% |
| 2022 | -1.82x | €-564.65 Million | €-577.61 Million | €309.87 Million | ▼ -22.0% |
| 2021 | -1.49x | €-552.35 Million | €-623.74 Million | €369.73 Million | — |